DEFA14A: Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion

Eli Lilly and Company announced a definitive agreement to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company, for approximately $1.2 billion in cash.

Summary

• Eli Lilly and Company will acquire Ventyx Biosciences, Inc. for an aggregate equity value of approximately $1.2 billion.
• Each share of Ventyx's common stock will be converted into the right to receive $14.00 per share in cash, without interest and less any applicable tax withholding.
• Each share of Ventyx's preferred stock will be converted into the right to receive $1,400.00 per share in cash, without interest and less any applicable tax withholding.
• The acquisition is focused on Ventyx's pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders.
• The transaction is expected to close in the first half of 2026, subject to Ventyx stockholder approval and customary regulatory clearances.
• Ventyx's board of directors has approved the merger.
• Directors, officers, and entities affiliated with New Science Ventures, collectively owning approximately 10% of Ventyx's outstanding common stock, have signed voting and support agreements to approve the transaction.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for Ventyx shareholders due to the significant premium offered in an all-cash transaction by a major pharmaceutical company. For Eli Lilly, it represents a strategic expansion into promising therapeutic areas, indicating a strong belief in Ventyx's pipeline.

Positives

• The acquisition price of $14.00 per common share represents a significant premium of approximately 62% to Ventyx's 30-day volume-weighted average trading price ended January 5, 2026.
• The all-cash transaction provides immediate and certain value to Ventyx shareholders.
• The acquisition strategically strengthens Eli Lilly's capabilities in inflammatory-mediated diseases, adding a clinical-stage pipeline of oral therapies, including NLRP3 inhibitors.
• Strong commitment to the transaction is demonstrated by voting and support agreements from Ventyx's directors, officers, and a key affiliate, representing approximately 10% of outstanding common stock.

Negatives

• Ventyx Biosciences will cease to exist as an independent publicly traded company, becoming a wholly-owned subsidiary of Eli Lilly.
• Ventyx shareholders will no longer participate in any potential future upside or growth of the company's pipeline beyond the acquisition price.

Risks

• Ventyx's common stockholders may not approve the adoption of the Merger Agreement.
• The Company may receive competing offers or acquisition proposals.
• Failure to (or delay in) receiving the required regulatory clearances for the Merger.
• A condition to closing of the Merger may not be satisfied (or waived).
• The closing of the Merger might be delayed or not occur at all.
• Diversion of management time and attention from ongoing business operations and opportunities.
• Response of competitors to the Merger.
• The Merger and its public announcement may affect Ventyx's operations and relationships with suppliers, business partners, management, and employees, including its ability to attract and retain key personnel.
• Outcome of any legal proceedings that could be instituted against the parties to the Merger.
• Risks inherent in drug research, development, and commercialization.
• Disruption in Ventyx's plans and operations attributable to the Merger.
• Changes in Ventyx's business during the period between announcement and closing of the Merger.
• The Merger (or its announcement) may affect Ventyx's stock price.
• Relationships with key third parties or governmental entities, regulatory changes and developments.
• Impact of global macroeconomic conditions, including trade and other global disputes and interruptions, related to tariffs, trade protection measures, and similar restrictions.

Future Outlook

The transaction is expected to close in the first half of 2026, pending Ventyx stockholder approval and customary regulatory clearances. Eli Lilly anticipates that the acquisition will strengthen its ability to deliver meaningful advances for patients by integrating Ventyx's clinical-stage pipeline of oral therapies, particularly NLRP3 inhibitors, across its focus areas of cardiometabolic health, neurodegeneration, and autoimmunity.

Management Comments

• Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president of Lilly Research Laboratories, stated that 'There is increasing evidence that inflammation is a key driver of many chronic diseases. Ventyx's clinical-stage pipeline addresses a critical need for better treatment options across diseases mediated by chronic inflammation and further strengthens our ability to deliver meaningful advances for patients living with challenging diseases across focus areas of cardiometabolic health, neurodegeneration and autoimmunity.'
• Raju Mohan, Ph.D., chief executive officer of Ventyx Biosciences, commented that 'Our portfolio of class-leading NLRP3 inhibitors modulate residual and chronic inflammation that is now recognized as a major risk factor in a host of neuroinflammatory, cardiometabolic and cardiovascular diseases. We believe that Lilly is an ideal strategic partner, with unparalleled resources, a passion for innovative oral drugs and a commitment to advance novel therapies that fill a vast unmet need for patients suffering from these debilitating diseases and disorders.'

Industry Context

This acquisition underscores a significant trend in the pharmaceutical industry towards targeting inflammatory-mediated diseases, which are increasingly recognized as drivers of various chronic conditions including cardiometabolic, neurodegenerative, and autoimmune disorders. Eli Lilly's strategic move to acquire Ventyx's pipeline of oral small molecule therapeutics, particularly NLRP3 inhibitors, positions it to expand its presence in these high-unmet-need areas, reflecting a broader industry focus on innovative oral drug development and precision medicine approaches to inflammation.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes a risk of legal proceedings being instituted against the parties to the Merger.
• Ventyx is obligated to promptly notify Eli Lilly of any actions, suits, or claims instituted or threatened against Ventyx, its subsidiaries, or its current/former directors or officers relating to the Merger Agreement or involving any Governmental Body.
• Eli Lilly has the right to participate in the defense and settlement of any such Company Litigation instituted by a stockholder of Ventyx in connection with the Merger.

Related Party Transactions

• Directors and officers of Ventyx, along with entities affiliated with New Science Ventures, who collectively own approximately 10% of Ventyx's outstanding common stock, have entered into voting and support agreements with Eli Lilly, agreeing to vote in favor of the merger.

Stakeholder Impact

• Shareholders (Ventyx): Will receive a significant cash premium for their common and preferred shares, providing immediate liquidity and a favorable return on investment.
• Employees (Ventyx): Will receive annual base salary/wage rate and target cash incentive compensation at least as favorable as prior to the merger for 12 months post-closing, along with substantially comparable broad-based employee benefits. Service will be credited for certain benefit plans.
• Management (Ventyx): Current directors and officers will resign and be replaced by Eli Lilly's designees, but their indemnification rights and D&O insurance will be maintained for six years.
• Customers, Suppliers, and Business Partners (Ventyx): The company will endeavor to preserve these relationships, but there is a risk of changes or disruptions due to the change in ownership.

Next Steps

• Ventyx will prepare and file a preliminary proxy statement with the SEC.
• Ventyx will mail the definitive proxy statement and a WHITE proxy card to each stockholder entitled to vote.
• Ventyx will establish a record date for, duly call, convene, and hold a special stockholder meeting to vote on the adoption of the Merger Agreement.
• Obtain the requisite approval of the Merger from Ventyx's stockholders.
• Obtain expiration or termination of the waiting period applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Obtain any other necessary regulatory clearances or affirmative approvals in required jurisdictions.
• File the Certificate of Merger with the Secretary of State of the State of Delaware.
• Ventyx will purchase a tail policy under its current directors and officers liability insurance policy.
• Ventyx will cause its securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time.

Key Dates

Recommendation

The filing details an all-cash acquisition of Ventyx Biosciences by Eli Lilly at $14.00 per common share, representing a substantial 62% premium over the 30-day volume-weighted average trading price. This offers Ventyx shareholders immediate and certain value, making it a highly attractive exit. The strategic rationale for Lilly, acquiring a pipeline of oral therapies for inflammatory-mediated diseases, suggests a strong fit and commitment to the deal. The support agreements from key shareholders further de-risk the transaction, making it a compelling 'strong buy' for Ventyx shareholders to capture the premium.

Keywords

Ventyx Biosciences, Eli Lilly, Acquisition, Merger, Biopharmaceutical, Inflammatory-mediated diseases, NLRP3 inhibitors, Oral therapies, Cardiometabolic disorders, Neurodegenerative diseases, Autoimmune disorders, Drug development, Clinical-stage, Pharmaceutical M&A